comprehensive -WSS

comprehensive

author：comprehensive 2025-09-30 08:50:11 - browse：1

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： NVIDIA and Google execs on the future of AI and drug discovery

hotspot

WSS

Cytokinetics CEO stresses company can launch heart drug on its own

Venture capitalist Bob Kocher on the state of digital health

Brazil's Neymar fined $3.3 million for illegal artificial lake at mansion outside Rio

HIV vaccine remains elusive. Immunologists keep trying new ideas

Data integrity in scientific journals requires "effort" by publishers, institutions

Ukraine holds disaster drills amid fears Russia could sabotage nuclear power plant

leisure time

comprehensive

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Glen Campbell's doctor discusses his public struggle with Alzheimer's

23andMe had bad news about my health. I wish a person had delivered it

Data integrity in scientific journals requires "effort" by publishers, institutions

As demand for Covid shots wanes, Moderna seeks its next success

HIV vaccine remains elusive. Immunologists keep trying new ideas

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The Democratic Party promised to overhaul its primaries. Doing that has been anything but simple

Supreme Court strikes down use of affirmative action

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

focus

Churchill Downs extends trainer Bob Baffert's ban through 2024

NASA releases new images of 'fingerprint

Kremlin open to talks over potential prisoner swap involving detained US reporter Evan Gershkovich

NASA releases new images of 'fingerprint

Venture capitalist Bob Kocher on the state of digital health

Solving academic medical centers' existential crisis

hotspot

hotspot

hotspot

entertainment